Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · February 08, 2024

Low-Dose vs Standard-Dose Olanzapine With Triple Antiemetic Therapy for Preventing Nausea and Vomiting in Patients With Solid Tumours After Highly Emetogenic Chemotherapy

The Lancet Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
Low-dose versus standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with solid tumours: a single-centre, open-label, non-inferiority, randomised, controlled, phase 3 trial
Lancet Oncol 2024 Feb 01;25(2)246-254, J Bajpai, V Kapu, S Rath, S Kumar, A Sekar, P Patil, A Siddiqui, S Anne, A Pawar, S Srinivas, P Bhargava, S Gulia, V Noronha, A Joshi, K Prabhash, S Banavali, R Sarin, R Badwe, S Gupta

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading